Addressing Ruxolitinib Resistance in Myelofibrosis

Video

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, addresses the management of patients with myelofibrosis after failure on ruxolitinib (Jakafi).<br /> &nbsp;

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, addresses the management of patients with myelofibrosis (MF) after failure on ruxolitinib (Jakafi).

Ruxolitinib failure is observed in a broad range of presentations and definitions, and Scherber says that a key difference should specifically be made between ruxolitinib refractory/resistant patients and ruxolitinib progressed/relapsed patients. Scherber says that she evaluates which category a patient falls into once they have failed on ruxolitinib, and then adjusts treatment accordingly.

Related Videos
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content